Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma

Lee, Won-Seop; Kim, Dae Hyeok; Shin, Sung‐Hee; Woo, Seoung-Il; Kwan, Jun; Park, Keum-Soo; Park, Sang‐Don; Yi, Hyeon-Gyu; Jeon, Sang-Hoon

doi:10.3349/ymj.2011.52.1.196

Cited by 14 publications

(14 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the last decades, however, resistance to carbapenems is increasing worldwide (Gopalakrishnan and Sureshkumar, 2010; Davies et al, 2011; Gogou et al, 2011; Lee et al, 2011a) and carbapenem-resistant A. baumannii strains are commonly resistant to all other classes of antibiotics as well, showing intermediate susceptibility to rifampicin and only being susceptible to tigecycline and colistin, although resistance to both antimicrobials has also recently been reported (Al-Sweih et al, 2011; Taneja et al, 2011). …”

Section: Antimicrobial Resistancementioning

confidence: 99%

The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace

Roca¹,

Espinal²,

et al. 2012

View full text Add to dashboard Cite

During the past few decades Acinetobacter baumannii has evolved from being a commensal dweller of health-care facilities to constitute one of the most annoying pathogens responsible for hospitalary outbreaks and it is currently considered one of the most important nosocomial pathogens. In a prevalence study of infections in intensive care units conducted among 75 countries of the five continents, this microorganism was found to be the fifth most common pathogen. Two main features contribute to the success of A. baumannii: (i) A. baumannii exhibits an outstanding ability to accumulate a great variety of resistance mechanisms acquired by different mechanisms, either mutations or acquisition of genetic elements such as plasmids, integrons, transposons, or resistant islands, making this microorganism multi- or pan-drug-resistant and (ii) The ability to survive in the environment during prolonged periods of time which, combined with its innate resistance to desiccation and disinfectants, makes A. baumannii almost impossible to eradicate from the clinical setting. In addition, its ability to produce biofilm greatly contributes to both persistence and resistance. In this review, the pathogenesis of the infections caused by this microorganism as well as the molecular bases of antibacterial resistance and clinical aspects such as treatment and potential future therapeutic strategies are discussed in depth.

show abstract

Section: Antimicrobial Resistancementioning

confidence: 99%

The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace

Roca¹,

Espinal²,

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Cardiac toxicity and cardiac adverse reactions are included under 'Warnings and Precautions' in the respective US labels for bortezomib and carfilzomib (http://www.velcade.com/files/pdfs/velcade_presc ribing_information.pdf). Case reports have described cardiac failure and other cardiotoxicity with bortezomib treatment in patients with MM and other cancers (Voortman & Giaccone, 2006;Enrico et al, 2007;Hacihanefioglu et al, 2008;Takamatsu et al, 2010;Dasanu, 2011;Lee et al, 2011;Bockorny et al, 2012;Gupta et al, 2012;Subedi et al, 2014). However, case reports do not provide a comprehensive picture of the cardiovascular risk profile of bortezomib.…”

Section: Introductionmentioning

confidence: 99%

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

et al. 2017

View full text Add to dashboard Cite

Summary This retrospective analysis aimed to establish the overall cardiac safety profile of bortezomib using patient‐level data from one phase 2 and seven phase 3 studies in previously untreated and relapsed/refractory multiple myeloma (MM). Seven clinically relevant primary [congestive heart failure (CHF), arrhythmias, ischaemic heart disease (IHD), cardiac death] and secondary (hypertension, dyspnoea, oedema) cardiac endpoints were defined based on MedDRA v16.0 preferred terms. 2509 bortezomib‐treated patients and 1445 patients in non‐bortezomib‐based control arms were included. The incidence of grade ≥3 CHF was 1·3–4·0% in studies in relapsed/refractory MM and 1·2–4·7% in previously untreated MM (2·0–7·6% all grades), with no significant differences between bortezomib‐ and non‐bortezomib‐based arms in comparative studies. Incidences of arrhythmias (1·3–5·9% grade ≥2; 0·6–4·1% grade ≥3), IHD (1·2–2·9% all grades; 0·4–2·7% grade ≥3) and cardiac death (0–1·4%) were low, with no differences between bortezomib‐based and non‐bortezomib‐based arms. Higher rates of oedema (mostly grade 1/2) were seen in bortezomib‐based versus non‐bortezomib‐based arms in one study and a pooled transplant study analysis. Logistic regression analyses of comparative studies showed no impact on cardiac risk with bortezomib‐based versus non‐bortezomib‐based treatment. Bortezomib‐based treatment was associated with low incidences of cardiac events.

show abstract

“…A myocardial biopsy excluded amyloid deposition. A pacemaker was inserted and the drug interrupted permanently [91].…”

Section: Bortezomibmentioning

confidence: 99%

“…Sinus bradycardia [64] Sunitinib, sorafenib AV conduction disturbances [83] Bortezomib Complete AV block Sinus bradycardia [86,88,[90][91][92] [88]…”

Section: Fludarabinementioning

confidence: 99%